ReviewEuropean journal of rheumatology2015
Recent advances in Takayasu's arteritis.
Review in European journal of rheumatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Update on Outcome Measure Development for Large Vessel Vasculitis: Report from OMERACT 12.The Journal of rheumatology · 2015Pooled it
- Comparison of the 2022 ACR/EULAR classification criteria with the 1990 ACR classification criteria for Takayasu arteritis.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025Article
- Analysis of proinflammatory cytokine responses in Takayasu arteritis.Archives of rheumatology · 2024Article
- Adolescent Takayasu's arteritis with hypertensive intracerebral hemorrhage: a case report and literature review.Frontiers in pediatrics · 2024Article
- Article
- [Comparison of diagnostic efficacy of different classification criteria for Takayasu arteritis in Chinese patients].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2022Article
- Takayasu's arteritis in an adolescent with fever of unknown origin: the contribution of PET-CT in the diagnosis.BMJ case reports · 2022Article
- The Epidemiology and Clinical Manifestations of Takayasu Arteritis: A Descriptive Study of Case Reports.Cureus · 2021Review
- Article
- Article
- Article
- Takayasu's arteritis: a unique ophthalmic presentation with CRAO and BRVO.BMJ case reports · 2019Article
- Audiovestibular Symptoms in Systemic Autoimmune Diseases.Journal of immunology research · 2018Review
- Takayasu's disease effects on the kidneys: current perspectives.International journal of nephrology and renovascular disease · 2018Review
- Multiple aneurysms and gastrointestinal involvement in Behcet's disease: A case report.Medicine · 2017Article
- Bilateral ocular ischemia-induced blindness as a presenting manifestation of Takayasu arteritis: a case report.Journal of medical case reports · 2017Article
- Recovery from Repeated Sudden Hearing Loss in a Patient with Takayasu's Arteritis Treated with Hyperbaric Oxygen Therapy: The First Report in the Literature.Case reports in otolaryngology · 2017Article
- Takayasu's Arteritis in Pregnancy: A Rare Case Report from a Tertiary Care Infirmary in India.Case reports in obstetrics and gynecology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Takayasu's arteritis (TAK) is a rare, chronic large-vessel vasculitis (LVV) that predominantly affects the aorta, its major branches, and the pulmonary arteries. Recent advances in the diagnosis, clinical course, disease assessment with biomarkers/imaging and new clinical tools, patient-reported outcomes, and new treatment options of TAK are discussed in this review. Conventional angiography, the gold standard method for initial diagnosis, appears to have been replaced with new imaging modalities such as magnetic resonance angiography (MRA) and 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) in recent years. MRA and FDG-PET are also promising for the assessment of disease activity. New tools for disease assessment such as Indian Takayasu's Arteritis Score 2010 (ITAS2010) and color Doppler ultrasound (CDUS) aim to better characterize and quantify disease activity; however, different imaging modalities in routine follow-up are not incorporated sufficiently in these approaches. Prognosis is possibly getting better, with lower mortality in recent years; however, it is difficult to assess the widely different vascular intervention rates among the clinical series. Leflunomide, tumor necrosis factor (TNF)-α antagonists, and tocilizumab are new options for patients resistant to conventional therapies. There is a clear need to develop a validated set of outcome measures for use in clinical trials of TAK. The Outcome Measures in Rheumatology (OMERACT) Vasculitis Working Group has taken on this task, finished a Delphi exercise with experts, and aims to develop a core set of outcomes for LVV in accordance with OMERACT Filter 2.0.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.